UB-421Innovative HIV Infectious Disease Therapeutic Monoclonal Antibody

  • Mechanism of Action

    UB-421 is an Fc-aglycosylated, non-T cell depleting, humanized IgG1 that targets domain 1 of CD4 receptor on CD4+ T cell surface, blocking entry of HIV into the cells via a competitive binding inhibition.

  • Features

    1. Competitive inhibition: 50-100 times stronger binding affinity to CD4 T cells than HIV.
    2. Neutralizes all HIV clades and subtypes regardless tropism, as well as HIV strains resistant to antiretrovirals, broadly neutralizing antibodies, CCR5 receptor antagonists, or ibalizumab.
    3. Inhibits both cell-to-cell and cell-free transmission of HIV.
    4. Modulates immune responses: Treg% and PD-1% reduction and CD8 expansion.
    5. Reduces HIV reservoir
  • Potential indication

    1. Substitution for antiretroviral therapy (HAART substitution),
    2. Treatment of multidrug resistant (MDR) HIV infection
    3. Functional cure for HIV infection.
  • Market Opportunity

    1. Overall market for anti-HIV drugs is US$ 24 billion. (IMS Health 2016)
  • Unmet need

    1. No drug for functional cure.
    2. Lack of long acting drug
    3. Limited option for multi-drug resistance.

UB-621Innovative Anti-HSV Monoclonal Antibody

  • Mechanism of Action

    UB-621 is a human IgG1 monoclonal antibody that targets conserved gD protein of Herpes simplex virus (HSV) type I and type II.

  • Features

    1. Neutralizes both HSV-1 and HSV-2
    2. Long half-life up to 25 days
    3. The leading antibody drug for treatment of HSV infection
    4. High binding affinity to the gD protein : 3.6 x 10-11 M
  • Potential indication

    1. Recurrent genital herpes
    2. Small molecule antiviral drug resistant HSV infection
    3. Prevention of neonatal HSV infection
  • Market Opportunity

    1. Global genital herpes treatment market size was about US$ 0.7 B in 2016.
  • Unmet need

    1. Chronic suppression is currently not available
    2. Drug resistance problem